- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02633982
GENERAL;GENeral Practitioners and Embolism pRevention in NVAF Patients Treated With RivAroxaban:reaL-life Evidence (GENeRAL)
Registry Study on the Effectiveness of Rivaroxaban in Patients With Non-valvular Atrial Fibrillation Managed by General Practitioners(GENERAL Study)
In atrial fibrillation patients,anticoagulant therapy with warfarin has an excellent stroke preventive. Meantime,Warfarin may also increase the risk of hemorrhagic events. Considering this,warfarin is a drug which puts a great burden on patients and medical providers.
With the population aging, the number of non-valvular atrial fibrillation patients is increasing, and a necessity that not only specialist but also general practitioners. Anticoagulant therapy with warfarin is not easy for general practitioners and is not commonly used among general practioners. In such circumstances, Rivaroxaban,a new oral direct factor Xa inhibitor,has become available. Rivaroxaban is administrated once a day and exert an anti- coagulant effect soon after administration. It hardly reacts with foods or other drugs and therefore does not require regular monitoring. GENERAL study is to investigate the effectiveness of stroke and systemic embolism in non-valvular atrial fibrillation patients when it is prescribed by general practioners in real life settings.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studieorter
-
-
Osaka
-
Suita, Osaka, Japan, 565-8565
- Rekrytering
- Japan Cardiovascular Research Foundation
-
Kontakt:
- Hisao Ogawa
- Telefonnummer: 2231 +81-6-6833-5012
- E-post: ogawah@ncvc.go.jp
-
Huvudutredare:
- Hisao Ogawa, M.D.
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Non-valvular atrial fibrillation patient who are prescribed Rivaroxaban by General practitioners
Exclusion Criteria:
- Patients are contraindicated for rivaroxaban
- Patients judged as inappropriate for this study by investigators
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Kohort
- Tidsperspektiv: Blivande
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Composite of symptomatic stroke (ischemic/hemorrhagic) and systemic embolism
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Major bleeding events (adapted ISTH standard)
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Non-major bleeding events(without Major Bleeding complications)
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Composite of symptomatic stroke(ischemic or hemorrhagic),systemic embolism,myocardial infarction/unstable angina pectoris and cardiovascular death
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Symptomatic stroke (ischemic or hemorrhagic)
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Symptomatic ischemic stroke
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Symptomatic hemorrhagic stroke
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Systemic embolism
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Acute myocardial infarction/unstable angina pectoris
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Cardiovascular death
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Deep vein thrombosis/pulmonary thromboembolism
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Transient ischemic attack
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Percutaneous coronary intervention /coronary artery bypass grafting
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
All cause death
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Comparison of primary outcome (composite of symptomatic stroke(ischemic/hemorrhagic) and systemic embolism) rate and Major Bleeding complications (adapted ISTH standard)rate between EXPAND study and FUSHIMI AF registry
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Adverse Event excluding hemorrhagic events
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Patients adherence related with stroke or systemic embolism
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Correlation with CHADS2 score or other risk factors and outcome events in Japanese patients who administered Rivaroxaban
Tidsram: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- GENeRAL/J
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Förmaksflimmer
-
Pusan National University HospitalHar inte rekryterat ännuHjärtimplanterbar elektronisk enhet | Atrial High Rate EpisodKorea, Republiken av
-
Atrial Fibrillation NetworkDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Deutsches Zentrum...AvslutadAtrial High Rate EpisoderÖsterrike, Belgien, Bulgarien, Tjeckien, Frankrike, Tyskland, Grekland, Ungern, Italien, Nederländerna, Polen, Portugal, Rumänien, Spanien, Sverige, Ukraina, Storbritannien, Danmark
-
Assiut UniversityIndragenASD2 (Secundum Atrial Septal Defect)
-
Centre Chirurgical Marie LannelongueRekryteringMedfödd hjärtsjukdom | Sinus Venosus Defekt | Sinus Venosus Atrial Septum DefektFrankrike
-
Karolinska InstitutetDanderyd HospitalRekryteringFörmaksflimmer | Förmaksfladder | Supraventrikulärt slag, för tidigt | För tidiga supraventrikulära beats | För tidigt förmakskomplex | Extrasystole, AtrialSverige